Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: An open-label, multicenter, randomized controlled trial

Journal of Hematology and Oncology

Volumn 10, Issue 1, 2017, Pages

  Li, Mei Feng ^a,b   Li, Xiao Li ^b   Fan, Kai Liang ^a,c   Yu, Ying Yi ^a   Gong, Jing ^d   Geng, Shu Ying ^e   Liang, Ya Feng ^b   Huang, Ling ^f   Qiu, Ji Hua ^a   Tian, Xing Han ^b   Wang, Wen Ting ^b   Zhang, Xiao Lu ^b   Yu, Qing Xia ^b   Zhang, Yuan Feng ^b   Lin, Peng ^b   Wang, Li Na ^e   Li, Xin ^a   Hou, Ming ^a   Liu, Lu Yi ^b   Peng, Jun ^a  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

^c SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d Yantai Economy Technology Development Zone Center for Disease Control and Prevention   (China)

^e Infectious Disease Hospital of Yantai   (China)

^f YANTAISHAN HOSPITAL   (China)

Author keywords

Desialylation; Oseltamivir; Platelet; Sepsis; Thrombocytopenia

Indexed keywords

ANTIBIOTIC AGENT; OSELTAMIVIR; ADHESION RECEPTOR; ASIALOGLYCOPROTEIN RECEPTOR; AUTOANTIBODY; BIOLOGICAL MARKER; ERYTHRINA LECTIN; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; N ACETYLNEURAMINIC ACID; PLANT LECTIN; RICINUS COMMUNIS AGGLUTININ-1; THROMBIN RECEPTOR;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLEEDING; CAUSE OF DEATH; CLINICAL OUTCOME; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY RATE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; OBSERVATIONAL STUDY; OPEN STUDY; PLATELET DESIALYLATION; PLATELET RECOVERY TIME; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; ANTIBODY SPECIFICITY; BLOOD; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; DRUG MONITORING; FLOW CYTOMETRY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; THROMBOCYTE; TREATMENT OUTCOME;

ADULT; ANTIBODY SPECIFICITY; ASIALOGLYCOPROTEIN RECEPTOR; AUTOANTIBODIES; BIOMARKERS; BLOOD PLATELETS; DRUG MONITORING; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; PLANT LECTINS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 85019105885     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-017-0476-1     Document Type: Article

References (45)

1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165-228.
2. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:2063.
3. Lim SY, Jeon EJ, Kim HJ, et al. The incidence, causes, and prognostic significance of new-onset thrombocytopenia in intensive care units: a prospective cohort study in a Korean hospital. J Korean Med Sci. 2012;27:1418-23.
4. Brogly N, Devos P, Boussekey N, et al. Impact of thrombocytopenia on outcome of patients admitted to ICU for severe community-acquired pneumonia. J Infect. 2007;55:136-40.
5. Moreau D, Timsit JF, Vesin A, et al. Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays. Chest. 2007;131:1735-41.
6. Sharma B, Sharma M, Majumder M, et al. Thrombocytopenia in septic shock patients - a prospective observational study of incidence, risk factors and correlation with clinical outcome. Anaesth Intensive Care. 2007;35:874-80.
7. Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28:1871-6.
8. de Stoppelaar SF, van't Veer C, van der Poll T. The role of platelets in sepsis. Thromb Haemost. 2014;112:666-77.
9. Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113:6511-21.
10. Neame PB, Kelton JG, Walker IR, et al. Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. Blood. 1980;56:88-92.
11. Andonegui G, Kerfoot SM, McNagny K, et al. Platelets express functional Toll-like receptor-4. Blood. 2005;106:2417-23.
12. Wilson JJ, Neame PB, Kelton JG. Infection-induced thrombocytopenia. Semin Thromb Hemost. 1982;8:217-33.
13. Francois B, Trimoreau F, Vignon P, et al. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997;103:114-20.
14. Xiang B, Zhang G, Guo L, et al. Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun. 2013;4:2657.
15. Yin H, Stojanovic-Terpo A, Xu W, et al. Role for platelet glycoprotein Ib-IX and effects of its inhibition in endotoxemia-induced thrombosis, thrombocytopenia, and mortality. Arterioscler Thromb Vasc Biol. 2013;33:2529-37.
16. Pockros PJ, Duchini A, McMillan R, et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2002;97:2040-5.
17. Torre D, Pugliese A. Platelets and HIV-1 infection: old and new aspects. Curr HIV Res. 2008;6:411-8.
18. Tavil B, Unal S, Aytac-Elmas S, et al. Weekly long-term intravenous immunoglobulin for refractory parvovirus B19 and Epstein-Barr virus-induced immune thrombocytopenic purpura. Turk J Pediatr. 2008;50:74-7.
19. Grewal PK, Aziz PV, Uchiyama S, et al. Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor. Proc Natl Acad Sci U S A. 2013;110:20218-23.
20. Grewal PK, Uchiyama S, Ditto D, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008;14:648-55.
21. Chen X, Varki A. Advances in the biology and chemistry of sialic acids. ACS Chem Biol. 2010;5:163-76.
22. Roggentin P, Schauer R, Hoyer LL, et al. The sialidase superfamily and its spread by horizontal gene transfer. Mol Microbiol. 1993;9:915-21.
23. Monti E, Bonten E, D'Azzo A, et al. Sialidases in vertebrates: a family of enzymes tailored for several cell functions. Adv Carbohydr Chem Biochem. 2010;64:403-79.
24. Tribulatti MV, Mucci J, Van Rooijen N, et al. The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents. Infect Immun. 2005;73:201-7.
25. King SJ, Hippe KR, Weiser JN. Deglycosylation of human glycoconjugates by the sequential activities of exoglycosidases expressed by Streptococcus pneumoniae. Mol Microbiol. 2006;59:961-74.
26. Manco S, Hernon F, Yesilkaya H, et al. Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis. Infect Immun. 2006;74:4014-20.
27. Sorensen AL, Rumjantseva V, Nayeb-Hashemi S, et al. Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood. 2009;114:1645-54.
28. Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell. 2003;112:87-97.
29. Hoffmeister KM, Josefsson EC, Isaac NA, et al. Glycosylation restores survival of chilled blood platelets. Science. 2003;301:1531-4.
30. Jansen AJ, Peng J, Zhao HG, et al. Sialidase inhibition to increase platelet counts: a new treatment option for thrombocytopenia. Am J Hematol. 2015;90:E94-95.
31. Jansen AJ, Josefsson EC, Rumjantseva V, et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIbalpha metalloproteinase-mediated cleavage in mice. Blood. 2012;119:1263-73.
32. Hata K, Koseki K, Yamaguchi K, et al. Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. Antimicrob Agents Chemother. 2008;52:3484-91.
33. Moore ML, Chi MH, Zhou W, et al. Cutting edge: oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. J Immunol. 2007;178:2651-4.
34. Shao L, Wu Y, Zhou H, et al. Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody. Platelets. 2015;26:495-7.
35. Thiolliere F, Serre-Sapin AF, Reignier J, et al. Epidemiology and outcome of thrombocytopenic patients in the intensive care unit: results of a prospective multicenter study. Intensive Care Med. 2013;39:1460-8.
36. Van der Linden T, Souweine B, Dupic L, et al. Management of thrombocytopenia in the ICU (pregnancy excluded). Ann Intensive Care. 2012;2:42.
37. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:762-74.
38. Greenberg J, Packham MA, Cazenave JP, et al. Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest. 1975;32:476-84.
39. Kotze HF, van Wyk V, Badenhorst PN, et al. Influence of platelet membrane sialic acid and platelet-associated IgG on ageing and sequestration of blood platelets in baboons. Thromb Haemost. 1993;70:676-80.
40. Choi SI, Simone JV, Jorney LJ. Neuraminidase-induced thrombocytopenia in rats. Br J Haematol. 1972;22:93-101.
41. Grottum KA, Jeremic M. Neuraminidase injections in rabbits. Reduced platelet surface charge, aggregation and thrombocytopenia. Thromb Diath Haemorrh. 1973;29:461-9.
42. Sakr Y, Vincent JL, Ruokonen E, et al. Sepsis and organ system failure are major determinants of post-intensive care unit mortality. J Crit Care. 2008;23:475-83.
43. Ospina-Tascon GA, Buchele GL, Vincent JL. Multicenter, randomized, controlled trials evaluating mortality in intensive care: doomed to fail? Crit Care Med. 2008;36:1311-22.
44. Cooper DJ, Rosenfeld JV, Murray L, et al. Decompressive craniectomy in diffuse traumatic brain injury. N Engl J Med. 2011;364:1493-502.
45. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007;100:27-40.